[New EMA drug approval: Nivolumab in association with chemotherapy as first line treatment for HER2-negative esophageal adenocarcinoma with PD-L1 expression (CPS≥5)]

Stanislas Quesada; Pauline Vaflard

doi:10.1016/j.bulcan.2021.11.012

[New EMA drug approval: Nivolumab in association with chemotherapy as first line treatment for HER2-negative esophageal adenocarcinoma with PD-L1 expression (CPS≥5)]

Bull Cancer. 2022 Feb;109(2):109-110. doi: 10.1016/j.bulcan.2021.11.012. Epub 2022 Jan 4.

[Article in French]

Authors

Stanislas Quesada¹, Pauline Vaflard²

Affiliations

¹ Institut régional du cancer de Montpellier (ICM), 208, avenue des Apothicaires, parc euromédecine, 34298 Montpellier cedex 5, France. Electronic address: [email protected].
² Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.

PMID: 34996599
DOI: 10.1016/j.bulcan.2021.11.012

No abstract available

Keywords: Adénocarcinome de l’œsophage; Esogastric junction; Esophageal adenocarcinoma; First-line; Immunotherapy; Immunothérapie; Jonction œsogastrique; Nivolumab; Première ligne.

Publication types

Letter

MeSH terms

Adenocarcinoma / drug therapy*
Adenocarcinoma / metabolism
Antineoplastic Agents, Immunological / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
B7-H1 Antigen / biosynthesis
Drug Approval
Esophageal Neoplasms / drug therapy*
Esophageal Neoplasms / metabolism
Europe
Humans
Nivolumab / therapeutic use*
Receptor, ErbB-2

Substances

Antineoplastic Agents, Immunological
B7-H1 Antigen
CD274 protein, human
Nivolumab
ERBB2 protein, human
Receptor, ErbB-2

Supplementary concepts

Adenocarcinoma Of Esophagus